Activation Capital Announces Frontier BioHealth Showcase Event
Ten innovative life sciences and healthtech companies enter 16-week accelerator.
Ten innovative life sciences and healthtech companies enter 16-week accelerator.
Activation Capital integrates entrepreneurship programs with strategic space-making to optimize the translation and value of regional life science discoveries, driving growth in pharmaceuticals, biotech, and medical devices.
Activation Capital celebrates the successful closeout of a GO Virginia grant, which laid the foundation for Central Virginia’s emergence as a hub for advanced pharmaceutical manufacturing, driving growth in infrastructure, workforce, and supply chain development.
The pharmaceutical and medical technology sectors face a critical challenge: a significant reliance on overseas production for key ingredients and chemical starting materials with insufficient capacity and economic incentive for domestic production.
New biohealth pre-accelerator program offers early-stage biotech founders’ essential skills and guidance to prepare for advanced stages, fostering innovation in the growing life sciences sector.
Ten innovative life sciences and healthtech companies enter 16-week accelerator.
Activation Capital launches Frontier BioHealth, an educational and support program offering training, targeted mentorship, and relationship building to help scale pharmaceutical, biotech, medical device, and health-focused consumer products companies.
The Biden-Harris administration, through the U.S. Department of Commerce’s Economic Development Administration (EDA), announced yesterday that the Richmond-Petersburg MSA (the Region) has been designated as an Advanced Pharmaceutical Manufacturing (APM) Technology and Innovation Hub (Tech Hub).
Activation Capital, an innovation ecosystem development organization, announced plans to develop the 102,000-square foot Innovation Center in the Bio+Tech Park in Richmond, Virginia.
Activation Capital, an innovation ecosystem development organization, today announced that it has received $15M in funding from the Commonwealth of Virginia to accelerate the development of Central Virginia’s life sciences sector, including expanding regional capacity for end-to-end essential medicine research, development, and manufacturing.